Clinical Trial Update: Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating a modified regimen of Ublituximab for relapsing multiple sclerosis, currently recruiting to assess safety, efficacy and phar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: RECRUITING